Table 4.
Treatment characteristics for schizophrenic users of first-generation long-acting injectable antipsychotics and second-generation long-acting antipsychotics.
| Treatment characteristics | Schizophrenic users of
FGA-LAI (n = 1020) |
Schizophrenic users of
SGA-LAI (n = 976) |
p valuea |
|---|---|---|---|
| Treatment characteristics of the index drug,b n (%) | |||
| First-generation LAI | |||
| Haloperidol decanoate | 201 (19.7) | 0 (0.0) | – |
| Fluphenazine decanoate | 353 (34.6) | 0 (0.0) | – |
| Second-generation LAI | |||
| Risperidone LAI | 0 (0.0) | 775 (79.4) | – |
| Paliperidone LAI | 0 (0.0) | 201 (20.6) | – |
| Zuclopenthixol decanoate | 355 (34.8) | 0 (0.0) | – |
| Flupentixol decanoate | 111 (10.9) | 0 (0.0) | – |
| Treatment characteristics of LAI-AP in the year following index date | |||
| Speciality of the principal prescriber, n (%) | |||
| Psychiatry | 811 (79.5) | 845 (86.6) | 0.00 |
| General practice | 203 (19.9) | 129 (13.2) | 0.00 |
| Other | 6 (0.6) | 1 (0.1) | 0.13* |
| Not available | 0 (0.0) | 1 (0.1) | 0.49* |
| Concomitant use of oral antipsychotics in the year following index date | |||
| Number of prescriptions of OAP per patient, mean (SD) | |||
| All OAP | 34.7 (75.7) | 31.0 (43.1) | 0.18 |
| First-generation OAP | 6.6 (31.8) | 3.2 (14.8) | 0.00 |
| Second-generation OAP | 28.1 (60.2) | 27.9 (39.0) | 0.93 |
| Clozapine | 3.8 (21.4) | 3.9 (15.3) | 0.91 |
| Characteristics of the prescriber of the index drug, n (%) | |||
| Speciality | |||
| Psychiatry | 777 (76.2) | 826 (84.6) | 0.00 |
| General practice | 236 (23.1) | 144 (14.8) | 0.00 |
| Other | 5 (0.5) | 4 (0.4) | 1.00* |
| Not available | 2 (0.2) | 2 (0.2) | 1.00* |
| Dispensing location | |||
| Inpatient | 82 (8.0) | 133 (13.6) | 0.00 |
| Emergency department | 22 (2.2) | 21 (2.2) | 0.99 |
| Psychiatric department | 260 (25.5) | 353 (36.2) | 0.00 |
| Outpatient | 397 (38.9) | 313 (32.1) | 0.00 |
| Private clinic | 112 (11.0) | 15 (1.5) | 0.00 |
| Other | 5 (0.5) | 3 (0.3) | 0.73* |
| Not available | 142 (13.9) | 138 (14.1) | 0.89 |
a
p value from chi-square test unless stated otherwise.
b
The index drug was defined as the first LAI-AP prescribed between 1 January 2008 and 31 March 2012.
*
p value from Fisher’s exact test.
LAI, long-acting injectable; FGA-LAI, first-generation long-acting injectable antipsychotic; LAI-AP, long-acting injectable antipsychotic; OAP, oral antipsychotic; SD, standard deviation; SGA-LAI, second-generation long-acting antipsychotic.